Cartesian Therapeutics (RNAC) Return on Assets: 2016-2025
Historic Return on Assets for Cartesian Therapeutics (RNAC) over the last 9 years, with Sep 2025 value amounting to -0.22%.
- Cartesian Therapeutics' Return on Assets rose 30.00% to -0.22% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.22%, marking a year-over-year increase of 30.00%. This contributed to the annual value of -0.21% for FY2024, which is 72.00% up from last year.
- Latest data reveals that Cartesian Therapeutics reported Return on Assets of -0.22% as of Q3 2025, which was down 10.76% from -0.20% recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' Return on Assets registered a high of 0.15% during Q3 2022, and its lowest value of -1.18% during Q4 2023.
- For the 3-year period, Cartesian Therapeutics' Return on Assets averaged around -0.39%, with its median value being -0.26% (2023).
- In the last 5 years, Cartesian Therapeutics' Return on Assets slumped by 130bps in 2023 and then skyrocketed by 109bps in 2024.
- Quarterly analysis of 5 years shows Cartesian Therapeutics' Return on Assets stood at -0.08% in 2021, then climbed by 21bps to 0.12% in 2022, then crashed by 130bps to -1.18% in 2023, then soared by 109bps to -0.08% in 2024, then climbed by 30bps to -0.22% in 2025.
- Its Return on Assets was -0.22% in Q3 2025, compared to -0.20% in Q2 2025 and -0.10% in Q1 2025.